The Technical Analyst
Biofrontera Inc. [BFRI]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Biofrontera Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.34% $1.670
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.50 mill |
| EPS: | -13.02 |
| P/E: | -0.130 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 5.09 mill |
| Avg Daily Volume: | 0.792 mill |
| RATING 2024-04-18 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.130 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.130 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.467 - 1.873 ( +/- 12.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-03 | Lanckriet Heikki | Buy | 0 | |
| 2023-05-18 | Monaco Erica L. | Buy | 76 336 | Common Stock |
| 2023-05-18 | Monaco Erica L. | Sell | 76 336 | Restricted Stock Units |
| 2023-05-18 | Luebbert Hermann | Buy | 95 420 | Common Stock |
| 2023-05-18 | Luebbert Hermann | Sell | 95 420 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 27.89 |
| Last 24 transactions |
| Buy: 1 247 993 | Sell: 171 756 |
Forecast:
16:00 - $1.670
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.670
Forecast 2: 16:00 - $1.670
Forecast 3: 16:00 - $1.670
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.670 (-2.34% ) |
| Volume | 0.0409 mill |
| Avg. Vol. | 0.792 mill |
| % of Avg. Vol | 5.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BFRI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest Press Releases
2024-03-26 16:30:00 - Press Release
Biofrontera Inc. Announces 2024 Annual Meeting Of Stockholders And Deadlines For Submission Of Stockholder Proposals
Woburn, ma / accesswire / march 26, 2024 / biofrontera, inc. (nasdaq:bfri) (the "company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 annual meeting of stockholders will be held on june 12, 2024 and that the close of business on april 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at the 2024 annual meeting. the exact time and location of the 2024 annual meeting will be specified in the company's proxy statement for the 2024 annual meeting.
2024-03-15 20:25:00 - Press Release
Correction: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results And Provides A Business Update
(this release corrects the release that was posted earlier on march 15, 2024 to update the consolidated balance sheets) conference call begins at 10:00 a.m. eastern time on monday, march 18, 2024 woburn, ma / accesswire / march 15, 2024 / biofrontera, inc. (nasdaq:bfri) (the "company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended december 31, 2023.
2024-03-15 18:10:00 - Press Release
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results And Provides A Business Update
Conference call begins at 10:00 a.m. eastern time on monday, march 18, 2024 woburn, ma / accesswire / march 15, 2024 / biofrontera, inc. (nasdaq:bfri) (the "company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended december 31, 2023.
2024-03-08 09:00:00 - Press Release
Biofrontera Inc. To Report Fourth Quarter And Full Year 2023 Financial Results On March 15, 2024
Woburn, ma / accesswire / march 8, 2024 / biofrontera inc. (nasdaq:bfri), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended december 31, 2023 on friday, march 15, 2024. the results will be released after the market close on friday, march 15 and the company will host a conference call on monday, march 18 at 10:00am eastern time.
2024-03-05 07:30:00 - Press Release
Medicus Pharma Ltd. Announces Appointment Of Erica Monaco As Chief Operating Officer
Provides corporate update on financing and investor relations toronto, ontario--(newsfile corp. - march 5, 2024) - medicus pharma ltd. (tsxv: mdcx) (fse: n46) ("medicus" or the "company") is pleased to announce the appointment of erica monaco as chief operating officer.
Latest News
2024-03-24 16:05:02 - InvestorPlace
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
2024-03-08 09:00:00 - Accesswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024. The results will be released after the market close on Friday, March 15 and the company will host a conference call on Monday, March 18 at 10:00am Eastern Time.
2023-11-22 11:17:39 - Zacks Investment Research
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2023-11-10 13:54:09 - Seeking Alpha
Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q3 2023 Earnings Conference Call November 10, 2023 10:00 AM ET Company Participants Tirth Patel - IR Hermann Luebbert - Chairman, CEO and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.
2023-11-09 13:33:20 - Zacks Investment Research
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-03 08:30:00 - Accesswire
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2023, after the close of the U.S. financial markets on Thursday, November 9, 2023. The Company will hold a conference call on Friday, November 10, 2023 beginning at 10:00 a.m.
2023-09-18 13:33:31 - Zacks Investment Research
All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-08-11 10:12:07 - Seeking Alpha
Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good morning everyone and welcome to the Biofrontera Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please also note today's event is being recorded.
2023-08-11 10:03:12 - Zacks Investment Research
Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $6.14 per share versus the Zacks Consensus Estimate of a loss of $5.14. This compares to loss of $8.80 per share a year ago.
2023-08-04 08:30:00 - Accesswire
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
WOBURN, MA / ACCESSWIRE / August 4, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2023 before the opening of the U.S. financial markets on Friday, August 11, 2023. The Company will hold a conference call that same day beginning at 8:30 a.m.